• Something wrong with this record ?

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients

B. Stiburkova, K. Pavelcova, M. Pavlikova, P. Ješina, K. Pavelka,

. 2019 ; 21 (1) : 77. [pub] 20190320

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20022835

Grant support
AZV 15-26693 A, RVO00023728 Ministerstvo Zdravotnictví Ceské Republiky - International
RVO VFN64165 Ministerstvo Zdravotnictví Ceské Republiky - International
NV15-26693A MZ0 CEP Register

BACKGROUND: ABCG2 is a high-capacity urate transporter that plays a crucial role in renal urate overload and extra-renal urate underexcretion. Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common. In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age. METHOD: The cohort was recruited from the Czech Republic (n = 234) and consisted of 58 primary hyperuricemia and 176 gout patients, with a focus on pediatric-onset patients (n = 31, 17 hyperuricemia/14 gouts); 115 normouricemic controls were used for comparison. We amplified, sequenced, and analyzed 15 ABCG2 exons. The chi-square goodness-of-fit test was used to compare minor allele frequencies (MAF), and the log-rank test was used to compare empirical distribution functions. RESULTS: In the pediatric-onset cohort, two common (p.V12M, p.Q141K) and three very rare (p.K360del, p.T421A, p.T434M) allelic ABCG2 variants were detected. The MAF of p.Q141K was 38.7% compared to adult-onset MAF 21.2% (OR = 2.4, P = 0.005), to the normouricemic controls cohort MAF 8.5% (OR = 6.8, P <  0.0001), and to the European population MAF 9.4% (OR = 5.7, P <  0.0001). The MAF was greatly elevated not only among pediatric-onset gout patients (42.9%) but also among patients with hyperuricemia (35.3%). Most (74%) of the pediatric-onset patients had affected family members (61% were first-degree relatives). CONCLUSION: Our results show that genetic factors affecting ABCG2 function should be routinely considered in a hyperuricemia/gout diagnosis, especially in pediatric-onset patients. Genotyping of ABCG2 is essential for risk estimation of gout/hyperuricemia in patients with very early-onset and/or a family history.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022835
003      
CZ-PrNML
005      
20201214124846.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-019-1860-8 $2 doi
035    __
$a (PubMed)30894219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stiburkova, Blanka $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic. stiburkova@revma.cz. Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. stiburkova@revma.cz.
245    14
$a The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients / $c B. Stiburkova, K. Pavelcova, M. Pavlikova, P. Ješina, K. Pavelka,
520    9_
$a BACKGROUND: ABCG2 is a high-capacity urate transporter that plays a crucial role in renal urate overload and extra-renal urate underexcretion. Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common. In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age. METHOD: The cohort was recruited from the Czech Republic (n = 234) and consisted of 58 primary hyperuricemia and 176 gout patients, with a focus on pediatric-onset patients (n = 31, 17 hyperuricemia/14 gouts); 115 normouricemic controls were used for comparison. We amplified, sequenced, and analyzed 15 ABCG2 exons. The chi-square goodness-of-fit test was used to compare minor allele frequencies (MAF), and the log-rank test was used to compare empirical distribution functions. RESULTS: In the pediatric-onset cohort, two common (p.V12M, p.Q141K) and three very rare (p.K360del, p.T421A, p.T434M) allelic ABCG2 variants were detected. The MAF of p.Q141K was 38.7% compared to adult-onset MAF 21.2% (OR = 2.4, P = 0.005), to the normouricemic controls cohort MAF 8.5% (OR = 6.8, P <  0.0001), and to the European population MAF 9.4% (OR = 5.7, P <  0.0001). The MAF was greatly elevated not only among pediatric-onset gout patients (42.9%) but also among patients with hyperuricemia (35.3%). Most (74%) of the pediatric-onset patients had affected family members (61% were first-degree relatives). CONCLUSION: Our results show that genetic factors affecting ABCG2 function should be routinely considered in a hyperuricemia/gout diagnosis, especially in pediatric-onset patients. Genotyping of ABCG2 is essential for risk estimation of gout/hyperuricemia in patients with very early-onset and/or a family history.
650    _2
$a ABC transportér z rodiny G, člen 2 $x genetika $7 D000070997
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a alopurinol $x terapeutické užití $7 D000493
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kohortové studie $7 D015331
650    _2
$a febuxostat $x terapeutické užití $7 D000069465
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetická predispozice k nemoci $x genetika $7 D020022
650    _2
$a genotyp $7 D005838
650    _2
$a dna (nemoc) $x diagnóza $x farmakoterapie $x genetika $7 D006073
650    _2
$a antiuratika $x terapeutické užití $7 D006074
650    _2
$a lidé $7 D006801
650    _2
$a hyperurikemie $x diagnóza $x farmakoterapie $x genetika $7 D033461
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavelcova, Katerina $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Pavlikova, Marketa $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic.
700    1_
$a Ješina, Pavel $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic.
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 21, č. 1 (2019), s. 77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30894219 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124846 $b ABA008
999    __
$a ok $b bmc $g 1595154 $s 1113511
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 21 $c 1 $d 77 $e 20190320 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
GRA    __
$a AZV 15-26693 A, RVO00023728 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
GRA    __
$a RVO VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
GRA    __
$a NV15-26693A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options